In vivo quantification of amyloid burden in TTR-related cardiac amyloidosis

Alexander Marco Kollikowski, Florian Kahles, Svetlana Kintsler, Sandra Hamada, Sebastian Reith, Ruth Knuechel, Christoph Roecken, Felix Manuel Mottaghy*, Nikolaus Marx, Mathias Burgmaier

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)


Cardiac transthyretin-related (ATTR) amyloidosis is a severe cardiomyopathy for which therapeutic approaches are currently under development. Because non-invasive imaging techniques such as cardiac magnetic resonance imaging and echocardiography are non-specific, the diagnosis of ATTR amyloidosis is still based on myocardial biopsy. Thus, diagnosis of ATTR amyloidosis is difficult in patients refusing myocardial biopsy. Furthermore, myocardial biopsy does not allow 3D-mapping and quantification of myocardial ATTR amyloid. In this report we describe a Tc-99m-DPD-based molecular imaging technique for non-invasive single-step diagnosis, three-dimensional mapping and semiquantification of cardiac ATTR amyloidosis in a patient with suspected amyloid heart disease who initially rejected myocardial biopsy. This report underlines the clinical value of SPECT-based nuclear medicine imaging to enable non-invasive diagnosis of cardiac ATTR amyloidosis, particularly in patients rejecting biopsy.

Original languageEnglish
Pages (from-to)291-294
Number of pages4
JournalIntractable & rare diseases research
Issue number4
Publication statusPublished - Nov 2017


  • Cardiac ATTR amyloidosis
  • nuclear cardiac imaging
  • quantification
  • amyloid burden
  • myocardial biopsy
  • cardiac magnetic resonance imaging

Cite this